BRCA1/2, ovarian reserve (AFC, AMH, ovarian response), ongoing pregnancy BRCA1/2, ovariele reserve (AFC, AMH, ovariele response), doorgaande zwangerschap
Conditions
Interventions
blood sample
Sponsors
Participating sites: UMC Utrecht, Maastricht UMC+, Academic Hospital Brussels, UMC Groningen, Academic Medical Center Amsterdam
Eligibility
Inclusion criteria
Inclusion criteria: Case group (BRCA mutation carriers) - Female age > 18 years and 18 years and < 40 years - Regular menstrual cycles (i.e. mean cycle length of 21-35 days) - First IVF with ICSI and PGD treatment cycle due to an indication unsuspected for reduced ovarian reserve status - Written informed consent
Exclusion criteria
Exclusion criteria: Case group (BRCA mutation carriers) - Ovarian surgery - Chemo therapy - Radiation therapy to the pelvis, lower abdomen or total body radiation - Known female endocrine or autoimmune abnormalities (i.e. Cushing syndrome, type I Diabetes Mellitus, hypothyroidism, hyperprolactinemia, adrenal insufficiency, hypoparathyriodism, myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus) - Body Mass Index > 35 kg/m2 - Polycystic Ovarian Syndrome (Rotterdam criteria) - Early follicular FSH > 15 IU/L - Known Human immunodeficiency virus (HIV) infection - Known female genetic abnormalities suspected for subfertility (structural or numerical abnormalities of the X-chromosome (i.e. Turner¡¯s syndrome, fragile X syndrome), or abnormalities of human autosomal functionally relevant genes, other than a BRCA mutation, suspected for subfertility Controle group (non suspected for BRCA mutation): - Ovarian surgery - Chemo therapy - Radiation therapy to the pelvis, lower abdomen or total body radiation - Known female endocrine or autoimmune abnormalities (i.e. Cushing syndrome, type I Diabetes Mellitus, hypothyroidism, hyperprolactinemia, adrenal insufficiency, hypoparathyriodism, myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus) - Body Mass Index > 35 kg/m2 - Polycystic Ovarian Syndrome (Rotterdam criteria) - Early follicular FSH > 15 IU/L - Known HIV infection - Known genetic abnormalities, suspected for subfertility (structural or numerical abnormalities of the X-chromosome (i.e. Turner¡¯s syndrome, fragile X syndrome), or abnormalities of human autosomal functionally relevant genes suspected for subfertility
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum AMH level | — |
Secondary
| Measure | Time frame |
|---|---|
| - AFC - Amount of poor response (less than 4 oocytes at retrieval or cancellation due to insufficient follicle growths, i.e. < 4 dominant follicles sized ¡Ý14 mm growing) - Number of retrieved oocytes (total amount and MII) after first cycle COH - Ongoing and clinical pregnancy rate | — |
Contacts
Public ContactF.J. Broekmans
Heidelberglaan 100
Outcome results
None listed